Network Pharmacology, Molecular Docking, and Experimental Validation on Guiluoshi Anzang Decoction Against Premature Ovarian Insufficiency
- PMID: 38757315
- DOI: 10.2174/0113862073291139240506114446
Network Pharmacology, Molecular Docking, and Experimental Validation on Guiluoshi Anzang Decoction Against Premature Ovarian Insufficiency
Abstract
Background and objectives: Premature Ovarian Insufficiency (POI) is a disease suffered by women under the age of 40 when ovarian function has declined, seriously affecting both the physical and mental health of women. Guiluoshi Anzang decoction (GLSAZD) has been used for a long time and has a unique therapeutic effect on improving ovarian function. This study aims to investigate the mechanism of GLSAZD in treating POI through network pharmacology, molecular docking, and experimental verification.
Methods: In this study, the active ingredients of Guiluoshi Anzang Decoction and the targets of POI were obtained from TCMSP, BATMANN-TCM, Uniprot, GeneCards, and other databases, and network pharmacology analysis was performed. Molecular docking was conducted to validate the affinity of the main active ingredient of GLSAZD to key POI targets. A POI SD rat model was established, and HE staining, ELISA, Real-time PCR, and Western blot experiments were performed to verify the predicted core targets and the therapeutic effects.
Results: 10 core targets and the top 5 ingredients were screened out. Molecular docking showed core targets AKT1, CASP3, TNF, TP53, and IL6 had stable binding with the core 5 ingredients quercetin, kaempferol, beta-sitosterol, luteolin, and Stigmasterol. GO and KEGG enrichment analysis demonstrated the mechanism involved in the positive regulation of gene expression, PI3K-AKT signaling pathway, and apoptosis signaling pathways. Animal experiments indicated GLSAZD could up-regulate the protein expression of p-PI3K and p-AKT1 and the mRNA expression of STAT3 and VEGF, down-regulate TP53 and Cleaved Caspase-3 protein expression in rat`s ovarian tissues and serum TNF-α and IL-6 protein levels, activate PI3K-AKT signaling pathway and inhibit the apoptosis signaling pathway.
Conclusion: GLSAZD treats POI through multi-component, multi-target, and multi-pathway approaches. This study provided evidence for its clinical application in treating POI and shed light on the study of traditional medicine of the Guangxi Zhuang Autonomous Region in China.
Keywords: Apoptosis signaling pathway; Experimental verification.; Guiluoshi Anzang Decoction; Molecular docking; Network pharmacology; PI3K/AKT signaling pathway.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Network pharmacology and experimental validation to explore the molecular mechanisms of Bushen Huoxue for the treatment of premature ovarian insufficiency.Bioengineered. 2021 Dec;12(2):10345-10362. doi: 10.1080/21655979.2021.1996317. Bioengineered. 2021. PMID: 34753385 Free PMC article.
-
Study on the active ingredients and mechanism of Huyang Yangkun Formula for treating premature ovarian insufficiency via chemical profiling, network pharmacology, and experimental validation.J Pharm Biomed Anal. 2025 Sep 15;263:116951. doi: 10.1016/j.jpba.2025.116951. Epub 2025 May 8. J Pharm Biomed Anal. 2025. PMID: 40344967
-
Elucidating the mechanisms of Buyang Huanwu Decoction in treating chronic cerebral ischemia: A combined approach using network pharmacology, molecular docking, and in vivo validation.Phytomedicine. 2024 Sep;132:155820. doi: 10.1016/j.phymed.2024.155820. Epub 2024 Jun 24. Phytomedicine. 2024. PMID: 39004032
-
Exploring the mechanism of action of Yiyi Fuzi Baijiang powder in colorectal cancer based on network pharmacology and molecular docking studies.Biotechnol Genet Eng Rev. 2023 Oct;39(2):1107-1127. doi: 10.1080/02648725.2023.2167765. Epub 2023 Feb 3. Biotechnol Genet Eng Rev. 2023. PMID: 36735641 Review.
-
Elucidation of the mechanism of Zhenbao pills for the treatment of spinal cord injury by network pharmacology and molecular docking: A review.Medicine (Baltimore). 2024 Feb 16;103(7):e36970. doi: 10.1097/MD.0000000000036970. Medicine (Baltimore). 2024. PMID: 38363936 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous